Professor Minghui Duan: The Central Role of Genetic Testing in Hematologic Malignancies and Its Guidance for Personalized Therapy

Professor Minghui Duan: The Central Role of Genetic Testing in Hematologic Malignancies and Its Guidance for Personalized Therapy

From July 11 to 13, 2025, the 9th Annual Hematologic Oncology Congress of the Chinese Society of Clinical Oncology (CSCO) was held in Harbin. The event brought together top experts from China and abroad to discuss key issues in hematologic malignancies, including leukemia, lymphoma, and multiple myeloma. Topics spanned basic research, innovative drug development, precision medicine, and clinical translation. At the congress, Professor Minghui Duan from Peking Union Medical College Hospital delivered a compelling presentation titled “Key Considerations and Value of Genetic Testing in Hematologic Malignancies.” In an exclusive interview with Oncology Frontier – Hematology Frontier, Professor Duan elaborated on the critical role and latest advances of genetic testing in the diagnosis and treatment of blood cancers, offering valuable guidance for clinical practice.
Professor Xiaojie Bian: Innovative Drug Development in Prostate Cancer Is Moving Beyond ARPIs with the Emergence of Multi-Target and Multi-Platform Strategies | 2025 Pujiang Prostate Cancer Congress

Professor Xiaojie Bian: Innovative Drug Development in Prostate Cancer Is Moving Beyond ARPIs with the Emergence of Multi-Target and Multi-Platform Strategies | 2025 Pujiang Prostate Cancer Congress

The 2025 Pujiang Prostate Cancer Academic Congress, held in conjunction with the CSCO Prostate Cancer Committee (CSCO-PC) Annual Meeting, the CACA Genitourinary Oncology Committee (CACA-GO) Prostate Cancer Meeting, and the Chinese Prostate Cancer Consortium (CPCC) Annual Conference, took place in Shanghai from June 27–28. With the theme “Global Insight · Chinese Practice · Precision Breakthrough,” the event brought together leading domestic and international experts to share cutting-edge progress and clinical experience in prostate cancer. During the conference, Professor Xiaojie Bian of Fudan University Shanghai Cancer Center spoke with Oncology Frontier – Urology Frontier to discuss the current landscape and future prospects of innovative drug development for prostate cancer.
CAH 2025 | Professor Jin Lu: Advancing High-Quality Development in Multiple Myeloma Care through Standardized Treatment, Data Integration, and Optimized Follow-up

CAH 2025 | Professor Jin Lu: Advancing High-Quality Development in Multiple Myeloma Care through Standardized Treatment, Data Integration, and Optimized Follow-up

From June 20 to 22, the 19th Annual Meeting of the Chinese Medical Doctor Association Hematology Branch and the 2025 China Hematology Conference (CAH 2025) was held in the historic city of Xi’an. As a major academic event in China’s hematology community, the conference maintained its core mission of “serving clinical practice,” with a strong focus on treatment standardization, practical application, and multicenter collaboration, fostering deep integration of academic exchange and clinical implementation. During the event, Oncology Frontier – Hematology Frontier interviewed Professor Jin Lu from Peking University People's Hospital, Executive Chair of CAH 2025, for an in-depth conversation on the highlights of this year’s conference and the development of multiple myeloma (MM) care in China.
Prof. Philip Kwong: New Strategies and Emerging Horizons in the Management of mHSPC

Prof. Philip Kwong: New Strategies and Emerging Horizons in the Management of mHSPC

The “2025 Pujiang Prostate Cancer Academic Conference,” held from June 27 to 28 in Shanghai, was jointly organized with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Chinese Anti-Cancer Association Genitourinary Oncology Committee (CACA-GO) Prostate Cancer Meeting, and the Annual Conference of the Chinese Prostate Cancer Consortium (CPCC). With the theme “Global Vision · Chinese Practice · Precision Breakthrough,” the event attracted numerous domestic and international experts to share the latest advances and real-world experiences in prostate cancer.